Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 21.5% in December

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 1,420,000 shares, a decrease of 21.5% from the November 30th total of 1,810,000 shares. Based on an average daily volume of 4,630,000 shares, the short-interest ratio is presently 0.3 days. Approximately 4.0% of the shares of the stock are short sold.

Athira Pharma Stock Performance

Shares of ATHA stock traded up $0.01 on Friday, hitting $0.55. 137,249 shares of the company’s stock traded hands, compared to its average volume of 1,537,925. The stock has a market capitalization of $21.26 million, a price-to-earnings ratio of -0.19 and a beta of 2.99. The company’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $1.57. Athira Pharma has a one year low of $0.41 and a one year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.05. As a group, sell-side analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Athira Pharma

Several institutional investors have recently added to or reduced their stakes in the company. Rothschild Investment LLC bought a new position in shares of Athira Pharma during the second quarter valued at about $34,000. XTX Topco Ltd bought a new position in Athira Pharma during the 2nd quarter valued at approximately $60,000. Invst LLC purchased a new stake in Athira Pharma in the 2nd quarter worth approximately $68,000. American Century Companies Inc. grew its position in shares of Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after buying an additional 3,333 shares during the last quarter. Finally, Forefront Analytics LLC increased its stake in shares of Athira Pharma by 126.0% during the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after buying an additional 25,979 shares during the period. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Analysts Set New Price Targets

ATHA has been the subject of several research analyst reports. Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $5.00 to $0.50 in a research report on Thursday, September 19th. JMP Securities lowered shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th. BTIG Research cut Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th. Finally, Rodman & Renshaw lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.